ArticleJournal of medical virology2022
Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Clinical manifestations of COVID-19 breakthrough infections: A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- Safe prolonged prophylactic use and tolerability of Ashwagandha following COVISHIELD™ vaccination over 24 weeks: a multicentre randomized double-blind placebo-controlled trial.Frontiers in medicine · 2026Trial
- COVID-19 primary infection, reinfection, and its associated clinical presentations.Frontiers in public health · 2026Article
- Breakthrough Infection and Death after COVID-19 Vaccination: A Physics Perspective.Journal of biomedical physics & engineering · 2025Article
- Revealing COVID-19 breakthrough infection rates among vaccinated individuals at a tertiary care centre in South India.Iranian journal of microbiology · 2025Article
- Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.Scientific reports · 2024Observational
- COVID-19 breakthrough infections in vaccinated individuals at BPKIHS, Nepal.BMC infectious diseases · 2024Article
- Presenting clinical symptoms of post-COVID-19 breakthrough infection: Predictors of mortality in a Middle Eastern population.Vaccine: X · 2024Article
- Unveiling parental perspectives: COVID-19 vaccination for children in India.Journal of family medicine and primary care · 2024Article
- Evaluation of CoVid-19 infection among vaccinated and unvaccinated individuals using biochemical markers.Bioinformation · 2024Article
- Uptake and impact of COVID-19 vaccination among HIV key populations: a cohort study from Tamil Nadu, India.Journal of rural medicine : JRM · 2023Article
- Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDNPJ vaccines · 2023Article
- COVID-19 vaccines and their underbelly: Are we going the right way?Health science reports · 2023Article
- Intertwined Dysregulation of Ribosomal Proteins and Immune Response Delineates SARS-CoV-2 Vaccination Breakthroughs.Microbiology spectrum · 2023Article
- Prediction of in-hospital mortality rate in COVID-19 patients with diabetes mellitus using machine learning methods.Journal of diabetes and metabolic disorders · 2023Article
- Clinical features and severe outcome predictors of COVID-19 vaccine breakthrough infection among hospitalized patients: results from Egypt severe acute respiratory infections sentinel surveillance, 2021-2022.BMC infectious diseases · 2023Article
- Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months.Human vaccines & immunotherapeutics · 2022Article
- Perception and Attitude Towards COVID-19 Vaccination Among the Elderly: A Community-Based Cross-Sectional Study.Cureus · 2022Article
- Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.Journal of medical virology · 2022Article
- Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines against COVID-19 provide immunity to deter severe morbidities associated with the infection. However, it does not prevent infection altogether in all exposed individuals. Furthermore, emerging variants of SARS-CoV-2 impose a threat concerning the competency of the vaccines in combating the infection. This study aims to determine the variability in adverse events and the extent of breakthrough infections in the Indian population. A retrospective study was conducted using a pre-validated questionnaire encompassing social, demographic, general health, the status of SARS-CoV-2 infection, vaccination, associated adverse events, and breakthrough infections in the Indian population. Informed consent and ethical approval were obtained as per Indian Council of Medical Research (ICMR) guidelines. Participants, who provided the complete information, were Indian citizens, above 18 years, and if vaccinated, administered with either Covishield or Covaxin, were considered for the study. Data have been compiled in Microsoft Excel and analyzed for statistical differences using STATA 11. The responses from 2051 individuals fulfilling the inclusion criteria were analyzed. Among 2051, 1119 respondents were vaccinated and 932 respondents were non-vaccinated. Among 1119 vaccinated respondents, 7 were excluded because of missing data. Therefore, out of 1112 vaccinated, 413 experienced adverse events with a major fraction of younger individuals, age 18-40 years, getting affected (74.82%; 309/413). Furthermore, considerably more females than males encountered adverse consequences to vaccination (p < 0.05). Among vaccinated participants, breakthrough infections were observed in 7.91% (88/1112; 57.96% males and 42.04% females) with the older age group, 61 years and above (odds ratio, 3.25 [1.32-8.03]; p = 0.011), and males were found to be at higher risk. Further research is needed to find the age and sex-related factors in determining vaccine effectiveness and adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.